MULTIPLE MYELOMA

Single-agent belantamab demonstrated anti-myeloma activity and a manageable safety profile in the DREAMM-2 phase 2 study.

During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma.

A 78-year-old woman was diagnosed with stage II multiple myeloma and was deemed transplant ineligible.

A 51-year-old man who presented with pallor and worsening fatigue on exertion was diagnosed with standard risk, stage II multiple myeloma.

A 78-year-old White woman was given a diagnosis of stage II multiple myeloma and was deemed transplant ineligible. Genetic testing showed deletion 17p.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

A 51-year-old patient who originally presented with pallor and worsening fatigue on exertion was diagnosed with standard-risk, stage II multiple myeloma.

Findings from the phase 1 MonumenTAL-1 trial demonstrate the clinical activity of talquetamab in patients with relapsed or refractory multiple myeloma.

A recent presentation during the 18th International Myeloma Workshop focused on updated efficacy and safety data for daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone after nearly 5 years of median follow-up in the phase 3 MAIA study.

Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.

Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.

Krina K. Patel, MD, MSc, discusses how she chooses treatment for her patients with early or late relapsed/refractory multiple myeloma.

Considerations for future unmet needs and novel therapies in multiple myeloma, followed by practical advice for community oncologists.

In the context of multiple myeloma, Peter Voorhees, MD, considers the role of doublet vs triplet therapy, initial therapy selection, and monitoring treatment response.

Peter Voorhees, MD, reflects on practical implications of the MAIA trial and how best to manage a patient with newly diagnosed multiple myeloma.

Updated results from the MAIA trial, which tested the addition of daratumumab to lenalidomide-dexamethasone therapy in patients with transplant-ineligible newly diagnosed multiple myeloma.

Expert insight on the optimal management of transplant-ineligible newly diagnosed multiple myeloma in light of available therapies and clinical data.

Peter Voorhees, MD, provides a broad overview on risk assessment and the goals of therapy in multiple myeloma management.

According to phase 1 data from the MagnetisMM-1 trial, elranatamab may be a good treatment option for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology Case-Base Roundtable event, Andrzej Jakubowiak, MD, PhD, led a discussion on new agents for the treatment of multiple myeloma.

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

Two year after being diagnosed with stage II multiple myeloma, a 78-year-old female patient was still receiving daratumumab plus lenalidomide maintenance and presented with mild fatigue during a routine follow-up.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.